By Melane Sampson
Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the natural caretaker functions of astrocyte cells, the company believes it can alter the trajectory of some of the most devastating and costly neurological conditions. Emerging data suggests broad therapeutic potential across neurodegenerative diseases as well, including Alzheimer’s disease, drug addiction, and spinal cord injury.
“Astrocytes are the most abundant cell type in the human brain and play an essential role in keeping neurons alive and functioning,” William S. Korinek, PhD, co-founder and CEO of Astrocyte, says in an interview with BioTuesdays.
He adds that after an injury, astrocytes restore ion balance, control swelling, and clear away toxic neurotransmitters. Acting as the brain’s frontline responders, the ability to enhance their natural protective activity provides a powerful therapeutic opportunity.
The company’s lead candidate, AST-004, is a novel small molecule entering multiple Phase 2 clinical trials. The intravenous formulation is designed for emergency or hospital use, while an oral, fast-dissolving tablet—suitable for concussions, mild TBI, and field use—is in preclinical development with support from federal funding agencies. The company envisions a future where AST-004 can be administered within 24 hours of brain injury, extending the therapeutic window far beyond what is possible with existing treatments.
Dr. Korinek explains that astrocytes function as highly connected metabolic hubs, interfacing with arteries, neurons, and other glial cells through thousands of branching processes. “A single astrocyte can interact with hundreds of thousands of synapses,” he says. “Given this remarkable connectivity, astrocytes regulate blood flow, support neuronal metabolism, stabilize ion gradients, and maintain the blood–brain barrier. They are central to brain energy management, and that makes them an ideal therapeutic target.”
Only about 5% of stroke patients currently receive pharmaceutical therapy, largely because today’s thrombolytic drugs require rapid imaging and have narrow treatment windows. AST-004 was designed to overcome those limitations. “Our vision is to treat essentially all stroke patients,” Dr. Korinek says. “AST-004 does not require imaging prior to use, and in preclinical studies it has shown efficacy even when administered many hours after injury. That’s a transformative opportunity.”
Astrocytes were identified in the 19th century, but their importance to brain function has only recently come into focus. “We’ve learned more about astrocytes in the last 15 years than in the previous hundred,” Dr. Korinek notes. “They modulate synaptic plasticity, regulate neurotransmitter clearance, control oxidative stress, and help organize the architecture of the brain. These discoveries have literally rewritten neuroscience textbooks.”
Astrocytes also signal using slow-propagating calcium waves—waves that coordinate metabolic activity across networks of cells. “This intracellular and intercellular calcium signaling is central to how astrocytes respond to stress,” Dr. Korinek says. “When adenosine triphosphate (ATP) is depleted during injury, adenosine levels rise as a distress signal. Activating the adenosine A1 and A3 receptors on astrocytes triggers calcium release, boosts mitochondrial metabolism, and drives a suite of intrinsic protective mechanisms. AST-004 is designed to amplify this natural response.”
To date, Astrocyte has raised more than $36 million, including equity investment from angel groups and foundations, alongside substantial grant support from the NIH and the U.S. Department of Defense. In 2022, the company completed its first Phase 1 study with funding support by the Medical Technology Enterprise Consortium. In 2024, the FDA cleared the Investigational New Drug application for Phase 2 evaluation in acute ischemic stroke.
Clinical trial design in stroke and TBI has advanced rapidly over the last decade. Modern imaging tools and biomarkers now allow researchers to select homogeneous patient groups tailored to the specific dynamics of an injury. Dr. Korinek emphasizes the importance of these advances. “In the past, stroke and TBI studies enrolled highly heterogeneous patient populations—different injury locations, severities, and timelines—and it was extremely difficult to detect true treatment effects,” he says.
“Today we can use biomarkers like GFAP and advanced imaging protocols to enrich our study populations, create more uniform cohorts, and really understand whether a therapy is working. This is a major reason why we believe our Phase 2 trials are well positioned for success.”
Astrocyte’s STARFAST Phase 2 concussion trial is underway in Australia among Australian-Rules football players—athletes who experience fast, high-energy impacts but without the confounding factor of frequent sub-concussive hits. “It’s a clean model for evaluating a single, well-characterized concussion,” Dr. Korinek says. Initial patients have been dosed, and the study is expected to read out at the end of 2026. The trial will evaluate safety, symptom recovery, and a suite of blood biomarkers reflecting neural injury and inflammation.
A second study, the COSMOS trial in the Netherlands, will enroll patients with mild but CT-visible TBI. “These patients often have small hemorrhages, contusions, or other acute findings that give us a clear radiographic baseline,” Dr. Korinek says. “We’ll be able to track neuroinflammation, blood–brain barrier integrity, and other imaging biomarkers over time. It’s a unique opportunity to correlate AST-004’s biological activity with meaningful clinical outcomes.”
The third study, the U.S.-based STELLAR Phase 2A/B trial, will evaluate large-vessel-occlusion stroke patients across dozens of hospitals. “We’ll be looking at whether AST-004 can slow lesion growth during the critical first days following stroke,” Dr. Korinek says. “If we see promising signals, we will smoothly transition into Phase 2B within the same program. It’s a very efficient design tailored to maximize insight while minimizing delay.”
AST-004 Reduces Growth Rate of Stroke Lesion
AST-004 is a small-molecule agonist of the adenosine A1 and A3 receptors, with strong blood–brain barrier penetration, more than 90% oral bioavailability, a half-life of approximately six to seven hours, and demonstrated safety margins up to 400 times the efficacious dose in preclinical models. “We’ve shown in multiple animal models—including large animals—that AST-004 enhances mitochondrial metabolism in astrocytes, strengthens their ability to maintain ionic stability, and reduces excitotoxicity,” Dr. Korinek asserts. “We aren’t just stopping further damage; in some cases we’ve seen partial reversal of injury. That’s exceptionally encouraging.”
The therapeutic window is also unusually broad. “In stroke models we’ve observed efficacy when administering AST-004 within 24 hours of injury,” he says. “The field has shifted from a time clock to a tissue clock. With modern imaging, we can identify patients who still have salvageable tissue many hours after onset. That is exactly the population our drug is designed for.”
The company’s oral formulation of AST-004 is designed to dissolve in seconds without water and to remain stable across temperature and moisture extremes—qualities particularly attractive to sports organizations, emergency responders, and military personnel. “You can carry it in a backpack and administer it immediately after a concussion,” Dr. Korinek says. “It’s simple, fast, and field-ready.”
Astrocyte’s scientific origins date back more than 20 years to work conducted at the University of Texas at San Antonio. “My co-founder, Dr. James Lechleiter, originally sought to suppress astrocyte activity in cancer models,” Dr. Korinek says. “Instead, the approach unexpectedly made astrocytes more resilient and protected surrounding neurons. It was pure scientific serendipity—and it led directly to the founding of our company.”
The conditions Astrocyte is targeting represent enormous unmet medical needs. An estimated 2.6 million patients with TBI visit emergency departments each year in the United States, while 5–10 million individuals experience concussions that often receive no treatment. The national economic burden of TBI is estimated at $77 billion annually. Stroke remains the second leading cause of death worldwide, with 800,000 cases per year in the U.S. alone and an economic burden of roughly $45 billion. “Strokes lead to more years of disability than all other neurological conditions combined,” Dr. Korinek says. “Nursing homes are filled with people who suffered strokes. The human and societal cost is staggering.”
Astrocyte’s team includes experienced pharma veterans, neuroscientists, and financial leaders. The company completed the first >$6 million close of a Series B financing in December 2025 to support its major milestones over the next 18 months. “We have a strong team, strong science, and multiple clinical programs advancing in parallel,” Dr. Korinek contends. “We believe AST-004 has the potential to be the first broadly applicable treatment for brain injury. The next 18 months will be transformative for us.”
He adds, “We’re targeting a central metabolic pathway in the brain with the potential for broad impact across neurological disorders. The opportunity is enormous, the need is urgent, and the data generated so far gives us confidence that AST-004 can make a meaningful difference.”
• • • • •
To connect with Astrocyte Pharmaceuticals or any other companies featured on BioTuesdays, send us an email at editor@biotuesdays.com.
